Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants

Hye Won Kwak, Hyo Jung Park, Seo Yeon Jung, Eun Young Oh, Sang In Park, Yeonhwa Kim, Hyeong Jun Park, Sohyun Park, You Jin Kim, Hae Li Ko, Jung Ah Lee, Hyeran Won, Yun Ho Hwang, Seo Yeon Kim, Se Eun Kim, Seoung Eun Bae, Minhyuk Yoon, Jae Ouk Kim, Manki Song, Su Jeen LeeKi Weon Seo, Kunse Lee, Dokeun Kim, Hun Kim, Sang Myeong Lee, So Hee Hong, Jae Hwan Nam

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Owing to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, the development of effective and safe vaccines has become a priority. The measles virus (MeV) vaccine is an attractive vaccine platform as it has been administered to children for more than 40 years in over 100 countries. In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vaccination. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the α, β, γ, and δ variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.

Original languageEnglish
Pages (from-to)1892-1901
Number of pages10
JournalVaccine
Volume41
Issue number11
DOIs
StatePublished - 10 Mar 2023

Bibliographical note

Publisher Copyright:
© 2023 Elsevier Ltd

Keywords

  • Measles virus vector
  • Neutralizing antibody
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants'. Together they form a unique fingerprint.

Cite this